Lords Mark Industries Ltd investor presentation summary

Investor presentation of 19 Aug 2026, summarised by AI from the filing.

Q1 FY27 topline ₹280 cr, bottom line ₹32 cr; management expects more than 20% revenue growth in FY27.

Key takeaways

1. Q1 FY27 results Q1 FY27 topline was around ₹280 cr and bottom line around ₹32 cr.
2. FY27 guidance Management expects more than 20% revenue growth year on year for FY27.
3. Medtech launch Sickle cell and Onco products are in development stage, with launches expected in Q4 FY27 or early Q1 FY28.
4. Growth driver Medtech products are expected to contribute no less than 30% of total revenue.
5. Risk Medtech products require ICMR and CDSCO approvals before launch.

Original filing on BSE

Lords Mark Industries Ltd earnings call, investor presentation and press release summaries

• Other events: Strategy deck (10 Sep 2026), Investor presentation (10 Sep 2026), Investor presentation (10 Sep 2026), Investor presentation (19 Aug 2026), Investor presentation (17 Aug 2026)